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The drug discovery and development process has undergone dramatic changes 
particularly in the last decade. Progress in drug discovery has been fueled by improvements in 
methodologies and technologies including automated HPLC, automated method development, 
LC-MS. LC-NMR and high-throughput purification methods. During the drug discovery and 
development process, rugged analytical methods are highly desirable to evaluate early drug 
targets, drug metabolism, pharmacokinetics, process research, preformulation and formulations. 
In view of the continuous demand for bioanalytical methods in drug discovery and impurity 
profiling method for maintaining the quality and safety of drugs; the present work has been 
proposed. The thesis has been divided into six chapters.  
Chapter 1 deals with a brief introduction to role of liquid chromatography in pharmaceutical 
analysis.  
Chapter 2 describes development and validation of a high-throughput LC-ESI-MS method for 
determination of an immunosuppressant drug sirolimus on dried blood spots using monolithic 
column. 
Chapter 3 deals with the synthesis of a molecularly imprinted polymer (MIP) followed by 
development and validation of a molecularly imprinted polymer based solid phase extraction 
method for determination of sitagliptin in rat plasma and urine.  
Chapter 4 describes the isolation and characterization of one of the potential process related 
impurities of phenazopyridine. 
Chapter 5 describes the enantiomeric separation and determination of adrafinil and its related 
substances. 
Chapter 6 discusses the evaluation of polysaccharide‐based chiral stationary phases for 
resolution of mirtazapine and its process related substances. 
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Chapter 1: Role of liquid chromatography in pharmaceutical analysis. 
This chapter gives a brief introduction to various roles of liquid chromatography in 
pharmaceutical analysis. In the modern pharmaceutical industry, HPLC is the major and integral 
analytical tool applied at all stages of drug discovery, development, and production. At each 
phase of development the analyses of varieties of samples are performed to adequately control 
and monitor the quality of the prospective drug candidates, excipients, and final products, which 
require bioanalytical as well as impurity profiling methods.  
Effective and fast method development requires a thorough understanding of HPLC 
principles and theory which lay a solid foundation for appreciating the many variables that are 
optimized during fast and effective HPLC method development and optimization. HPLC basics, 
types of chromatography, detectors, method development and validation are discussed in brief 
in this chapter. Hyphenated techniques such as LC-MS and LC-NMR were also discussed. In 
addition, a description of the specifics of the latest advancements in fast, chiral and other 
modern LC techniques are included. In lieu of continuous demand of bioanalytical and impurity 
profiling method, five drugs viz. sirolimus, sitagliptin, phenazopyridine, adrafinil, mitrazapine 
were chosen and following objectives had been set: 
A. Development and validation of a high throughput LC-ESI-MS method for determination 
of immunosuppressant drug sirolimus on dried blood spots using monolith column. 
B. Development and validation of a molecularly imprinted polymer based solid phase 
extraction of anti-diabetic drug sitagliptin in rat plasma and urine using zwitterionic 
hydrophilic interaction liquid chromatography (ZIC-HILIC). 
C. Isolation and characterization of one of the potential process related impurities of 
phenazopyridine. 
D. Enantiomeric separation and determination of adrafinil and its related substances 
E. Evaluation of polysaccharide‐based chiral stationary phases for resolution of mirtazapine 
and its process related substances 
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Chapter 2: Development and validation of a LC-ESI-MS method for determination of 
sirolimus on dried blood spots. 
Immunosuppressive agents are used to avoid rejection of transplanted organs by body 
immune system. There are various classes of immunosuppressive agents. Sirolimus belongs to 
mTOR (mammalian target of rapamycin) class of immunosuppressive agents which potently 
inhibit T-cell proliferation. Therapeutic index of sirolimus is narrow, so its blood level 
concentration needs to be analyzed regularly in ng/mL level in transplant patients. It is difficult 
for a patient to go regularly to clinic to provide blood sample for analysis. 
 In this chapter the suitability of a dried blood spot (DBS) technique was evaluated for 
sample collection. A patient can collect blood samples from finger prick on a blood spot card 
without much special training to a clinic for analysis. A high-throughput LC–ESI-MS method 
for screening of sirolimus on DBS was developed and validated. It involves solvent extraction 
of a punch of DBS followed by reversed-phase LC on a relatively new monolithic column 
consisting of a silica rod with bimodal pore structure and detection by ESI-MS.  
The analysis was less than 3 min with a very low backpressure at a flow rate of 0.5 
mL/min [Mobile phase A/B: 20/80, v/v; A: 0.01% (v/v) formic acid in water, B: methanol 
containing 0.01% (v/v) formic acid]. The method can analyze more than 100 samples in an 8 h 
working day, including sample preparation. The assay was linear from 1 to 100 ng/mL. The 
mean recovery was 92.42%. The mean inter-day and intra-day precisions were 1.23 and 1.41%, 
respectively.  
The developed method is simple, rapid and useful for clinical applications. The validated 
method was demonstrated to be accurate, precise, and robust and complied with the regulatory 
guidelines. Robustness of the method was tested by means of DOE technique. The stability of 
sirolimus on DBS samples stored in dark at 4°C for 90 days demonstrated that the samples can 
be stored for long periods of time before analysis. The effect of mobile phase flow rate on the 
performance of monolithic and particulate columns was also evaluated. 
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Chapter 3: Development and validation of a molecularly imprinted solid phase extraction 
method for determination of sitagliptin in rat plasma and urine. 
Antidiabetic drugs treat diabetes mellitus by lowering glucose levels in the blood. There 
are different classes of antidiabetic drugs. Sitagliptin (belongs to DPP-IV inhibitor class) is a 
relatively new drug approved for treatment of diabetes. The current methods for analyzing 
sitagliptin in blood and urine are not only time consuming and require expensive 
instrumentation but also affected by matrix effects and have low recoveries. Plasma 
phospholipids are one of the major contributing sources of matrix effects in protein precipitation 
based sample preparation techniques. 
 A novel water-compatible molecularly imprinted polymer was synthesized and used for 
selective solid phase extraction of sitagliptin in rat plasma and urine. The effects of progenic 
solvents, pH, cross-linker and amount of monomer were studied to optimize the efficiency and 
selectivity. The adsorption kinetics and isotherms were measured. The molecularly imprinted 
polymer (MIP) showed good specific adsorption capacity with an optimum of 180 mg/g at pH 
7.5 and selective extraction of sitagliptin from rat plasma and urine. The recovery of sitagliptin 
from rat urine and plasma was >98%.  
 
Figure: Synthesis process for sitagliptin imprinted polymer. 
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Sitagliptin is relatively a polar compound having high solubility in water and not retain 
properly on C18 column. Zwitterionic hydrophilic interaction liquid chromatography (ZIC-
HILIC) is a best choice to analyze such types of polar compound which were earlier cannot be 
analyzed without prior derivatization. The HPLC method was developed using Merck ZIC-
HILIC Column (100mm×4.6mm×5μm).Mobile phase, ACN and 15 mM ammonium acetate (pH 
4.5) 90:10,v/v. Analysis was carried out under isocratic conditions using a flow rate of 
0.4mL/min at 25°C. The chromatograms were recorded at 268 nm using a PDA detector. The 
limits of detection (LOD) and quantification (LOQ) were 0.03 and 0.10 μg/mL respectively. 
Chapter 4: Isolation and characterization of a potential process related impurity of 
phenazopyridine 
Drugs can be dangerous if there is no adequate control over their manufacture, storage 
and distribution. The impurity profile of a drug substance is critical to its safety assessment and 
its manufacturing process. Because the impurities are usually process related, they are most 
probably structurally similar to the synthesized target drugs.  
During the process development of phenazopyridine HCl bulk drug, a potential impurity 
was detected in the routine impurity profiles by HPLC. This impurity was collected using semi-
preparative HPLC. The semi-preparative HPLC was performed with Inertsil ODS 3V 
(10mm×250mm; particle size 5μm) column using water/ACN (30:70, v/v) as a mobile phase at 
a flow rate of 5.0 mL/min and the detector was maintained at 254 nm.  Using MS/MS and 
multidimensional NMR techniques, the trace level impurity was unambiguously identified to be 
3-phenyl-5-phenylazo-pyridine-2,6-diamine after its isolation from phenazopyridine HCl by 
semi-preparative HPLC. The formation of the impurity was discussed. 
 Summary 
 
180 
 
 
Figure: The mechanism of formation of the impurity of phenazopyridine. 
Chapter 5: Enantiomeric separation and determination of adrafinil and its related 
substances 
Metabolic and regulatory processes mediated by biological systems are sensitive to 
stereochemistry and different responses may often be observed comparing the activities of a pair 
of enantiomers. Chiral molecules are constituents of a large proportion of therapeutic agents, 
since the role of stereochemical factors in toxicity of chemotherapeutic drugs is vital. Analytical 
methods for controlling the enantiomeric purity of drug substances and their intermediates play 
a key role in the process of drug development.  
A rapid and reliable high-performance liquid chromatographic method for resolution of 
enantiomers of adrafinil, a novel vigilance promoting agent, and its synthetic intermediates was 
developed. The separation was carried out on a Chiralcel OJ-H colimn using n-hexane–ethanol 
(62:38 v/v) as a mobile phase. The detection was carried out at 225 nm using a photodiode array 
(PDA) detector. The optical rotation and order of elution of enantiomers were assigned using a 
polarimetric detector. Chromatographic parameters: retention factor (k’), resolution (Rs) of R-
(+)-adrafinil, S-(-)-adrafinil, I, II, III and IV on Chiralcel OJ-H wee also determined. The 
method is suitable not only for process development of adrafinil but also for quality assurance 
of bulk drugs and pharmaceuticals. 
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Chapter 6: Evaluation of polysaccharide‐based chiral stationary phases for resolution of 
mirtazapine and its process related substances. 
Mirtazapine is a tetracyclic antidepressant that finds widespread use as a racemate in the 
treatment of patients with severe depression. Investigations have revealed that the 
(S)‐enantiomer of mirtazapine has better potential in the treatment of depression because of its 
high binding affinity with α2-adrenergic, 5-HT2 and 5-HT3 receptors. Thus, the development of 
single enantiomers as a new active pharmaceutical ingredient is of great importance because 
biological systems interact with and metabolize them differently.  
High‐performance liquid chromatographic methods were developed for separation of the 
enantiomers of mirtazapine and its four process‐related substances  The direct separations were 
achieved on chiral stationary phases containing amylose tris(3,5‐dimethylphenylcarbamate) 
(Chiralpak® AD‐H), cellulose tris(3,5‐dimethylphenylcarbamate) (Chiralcel® OD‐H) and 
cellulose tris(4‐methylbenzoate) (Chiralcel® OJ‐H ). The experimental data were utilized to 
discuss the effects of the mobile phase composition, the nature of the alcoholic modifier and the 
specific structural features of the analytes on retention and separation. The elution sequence was 
determined under the optimized separation conditions. 
